06-27-2004, 11:33 PM #1
Dbol and Postmenopausal Osteoporotic Females
Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass
To assess the efficacy of methandrostenolone in the treatment of osteoporosis a 26-mo double-blind study was performed with 13 treated and 13 control (placebo) postmenopausal osteoporotic females.^Drug effect was assessed primarily by determinations of total body calcium (TBC) by neutron activation analysis, essentially a measurement of total bone mineral mass.^Results in the 16 patients completing the study (10 treated and 6 placebo) as well as in all 26 patients participating in the study, showed significant (p < 0.01) differences in the change in TBC between treated and control groups.^The drug effect appeared to persist throughout the 26-mo observation period.^Thus these data strongly suggest that long-term use of methandrostenolone in postmenopausal osteoporosis prevented bone loss; the possibility that it increased bone mass above initial values is less certain.
Univ. of Washington, Seattle
2001 May 13
Chestnut, C.H. III ; Nelp, W.B. ; Baylink, D.J. ; Denney, J.D.
Users Browsing this Thread
There are currently 1 users browsing this thread. (0 members and 1 guests)